Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company’s LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis. The three randomized, double-masked, dose-ranging and placebo-controlled LUMINATE trials enrolled 558 patients at 56 sites in 7 countries, including 218 patients with active non-infectious uveitis with posterior manifestation of the disease, 232 patients with clinically quiescent disease, and 108 patients with active uveitis with anterior manifestation of the disease.
LX211 is designed for use as an oral immune-modulatory agent to treat the forms of non-infectious uveitis that require systemic treatment, including posterior, intermediate and panuveitis, allowing for tapering of systemic corticosteroids to 5 mg or less per day. LX211 is a novel and proprietary next-generation calcineurin inhibitor for ophthalmic use.
For more information call (201) 946-0551 or visit www.luxbio.com.